Background Platelet activating factor (PAF) is a potent mediator of inflammation. Inhalation of PAF causes acute bronchoconstriction and a transient fall in white blood cell count in humans. Salmeterol inhibits pulmonary inflammation induced by PAF in guinea pigs. Methods The effect of salmeterol on effects induced by PAF was investigated in eight normal subjects who inhaled salmeterol (50 pg) twice daily or a matched placebo for one week before challenge with PAF. Blood samples were taken from a forearm catheter for total white cell and neutrophil counts before and for 30 minutes after administration of PAF (48 ug) through a Mefar dosimeter. Blood films were stained for unsegmented neutrophils before and after treatment with PAF on a placebo day. Results Mean baseline total white cell counts and neutrophil counts did not differ on the two days. Mean baseline sGaw was significantly higher after inhaled salmeterol (1'84 (95% Cl 1-45-2-23) s-'kPa'1) than after placebo (1-53
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(1-241-82)). After placebo mean total white cell counts, neutrophil counts, and sGaw were reduced to 60 (43-78)%, 39 (14-64)%, and 82 (71-93)% of baseline respectively five minutes after inhaled PAF. After salmeterol treatment mean reductions five minutes after inhaled PAF were 59 (45-73)%, 40 )%, and 82 (71-93)% of baseline respectively. At 30 minutes after treatment with PAF the neutrophil count rebounded to 143 (82-204)% of baseline after placebo and to 127 (93-161)% after inhaled salmeterol. There was no significant difference in the percentage of immature neutrophils before and after treatment with PAF (2-0 (0-5-2-6)% compared with 3-9 (2'2-5'6)%. In a recent study in normal subjects salbutamol had a partial inhibitory effect on bronchoconstriction induced by PAF but had no effects on changes in circulating white cell number.8
The aim of the present study was to investigate whether salmeterol could modulate the inflammatory effects of inhaled PAF in human subjects as it did in guinea pigs. Our hypothesis was that changes in circulating white cell numbers reflect changes in white cells in tissues, particularly the lung. We examined changes in circulating peripheral blood cells and also effects on airways in normal subjects.
Methods

SUBJECTS
Two normal female and six normal male volunteers from hospital and laboratory staff were studied. None of the subjects had any history of asthma. None had suffered any recent chest infection and no subjects were taking any medication. None were atopic and one subject was an ex-smoker. Mean Blood samples were drawn from a cannula placed in a forearm vein for total white blood cell and neutrophil counts before and for 30 minutes after administration of PAF.
PAF INHALATION CHALLENGE
PAF (Bachem Inc, California) was dissolved and stored in aliquots at a concentration of 10 mg/ml in 100% ethanol at -77°C. On the morning of each study PAF was diluted to 2 mg/ml in 0-9% saline containing heat treated human serum albumin at a final concentration of 0 04%. The PAF aerosol was delivered from a Mefar dosimeter (Brescia, Italy) driven by compressed air at a pressure of 1-5 kg/M2, with a one second actuation time and five seconds between puffs. Output was measured as 12 ,ul for each puff. Each subject received two puffs (48 jg PAF). Airways response to PAF was measured as changes in sGaw and in FEV,.
Measurements were made before inhalation of PAF (baseline) and seven, 12, 17, and 32 minutes after inhalation of PAF.
MEASUREMENT OF CIRCULATING CELLS
Duplicate venous blood samples (2 x 2 ml) were collected five minutes before and one, two, three, five, 10, 15, and 30 minutes after inhalation of PAF for determination of total white blood cell and neutrophil counts. Cell counts, including total and differential leucocyte counts and platelet counts, were determined in each of the paired samples by automatic analyser (Sysmex E500) and mean values were recorded. Coefficients of variation were 1-8% for total leucocyte counts and 6% for neutrophil counts.
An independent observer, unaware of the patient protocol, examined blood films prepared and stained by a routine May-Grunwald Giemsa method to look for evidence of newly released immature neutrophils. Films from samples collected at -5 and + 30 minutes on a placebo day were coded and examined in random order. A manual differential count was performed on 100 white blood cells on the two films from each subject. Particular care was taken to distinguish between mature segmented neutrophils and less mature unsegmented band forms. (1 2-1-8) s-' kPa~') (figure). Baseline FEV1 after treatment with salmeterol was higher but did not differ significantly from that after placebo. There was some variation in airway response to PAF in the different subjects. One subject showed no significant change in sGaw after PAF on either study day. Values for sGaw after treatment with salmeterol were significantly higher than after placebo 10 and 15 minutes after inhaled PAF (p < 0-05 for both), although the percentage baseline values did not differ. Circulating lymphocyte and platelet counts did not change significantly with salmeterol treatment compared with placebo or after inhaled PAF on either study day. Before inhalation of PAF band neutrophils represented a mean 2-0 (0-5-2-6)% of the total neutrophil count and 3-9 (2-2-5-6)% at 30 minutes after PAF inhalation. There was no significant change (p = 0-10) in the number of immature neutrophils before or after inhalation of PAF. Thus the slight rise in total neutrophils was not due to significant release of immature granulocytes from the bone marrow.
Discussion
We have confirmed previous findings that inhaled PAF causes transient bronchoconstriction and changes in neutrophil count in human subjects. Salmeterol at a standard clinical dose (50 Mg) inhaled twice daily for one week did not significantly modify the reduction in neutrophil count after inhaled PAF or the subsequent rebound neutrophilia. Salmeterol caused baseline bronchodilatation, confirming compliance, but did not prevent the bronchoconstrictor response to inhaled PAF compared with placebo.
This study precisely defines the time course of the effect of PAF on neutrophils. The first reduction was seen at three minutes with the maximal effect at five minutes as previously documented.78"' Salmeterol had no effect on the time course, or on the degree of leucopenia, or on subsequent rebound neutrophilia compared with placebo, and this was consistent with a previous study of a single dose of inhaled salbutamol. 8 The lack of effect on circulating neutrophils shown here suggests that salmeterol is unlikely to modulate pulmonary sequestration of neutrophils'2 although this has not been studied directly. This conflicts with the inhibitory effect of salmeterol on migration of neutrophils into guinea pig lung3 and skin2 and pulmonary accumulation of eosinophils induced by PAF. 3 The hypothesis that changes in pulmonary white cell numbers are adequately mirrored by changes in the circulation has not been tested but radiation dose prevented examination in a study of similar design to this.'2 It may be possible to pursue this with prostacyclin, which has been suggested to modify circulating white cell changes after inhalation of PAF. '4 The mechanism of bronchoconstriction induced by PAF in humans remains unknown. Cholinergic nervous pathways are not involved. 7 The role of histamine is unclear as chlorpheniramine produced partial inhibition7 whereas other studies with different H, blockers had no effect.'5 16 In animals, secondary mediator release after treatment with PAF involves leukotriene and cyclo-oxygenase products including thromboxane A2. ' A standard clinical bronchodilator dose of salmeterol was used that would have been expected to block contraction of bronchial smooth muscle. The lack of protective effect of salmeterol suggests that airway narrowing induced by PAF may be due to airway oedema as PAF is known to be a potent mediator of microvascular leakage.5 This would also be consistent with the findings that acute protection by salbutamol was much less for PAF than equivalent bronchoconstriction induced by methacholine.5 Salmeterol produced bronchodilatation but did not inhibit PAF induced airway narrowing, cough, vasodilator effects, or neutrophil changes. These results conflict with the inhibitory effect of salmeterol on lung inflammation in guinea pigs but are consistent with the lack of effect of salbutamol in humans. Any antiinflammatory effect of salmeterol is therefore unlikely to be mediated through PAF. The only evidence of an anti-inflammatory effect of salmeterol in vivo in humans comes from the inhibition of the late phase reaction to allergen in atopic asthmatic patients. 4 There has been some discussion of the significance of these results22 in the light of baseline bronchodilatation of the type seen in our study. No effect of salmeterol on inflammatory indicators of allergen response was found. 23 We have no evidence to support an anti-inflammatory effect of salmeterol.
